H.C. Wainwright raised the firm’s price target on Precigen (PGEN) to $6 from $4 and keeps a Buy rating on the shares. The firm believes 2025 is a pivotal year for Precigen and expects a “robust launch” of PRGN-2012.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGEN:
- Biotech Alert: Searches spiking for these stocks today
- Precigen Secures $79M Financing for 2025 Launch
- Stifel thinks Precigen stock set to rebound after capital secured, BLA submitted
- Precigen submits BLA with request for priority review to FDA for PRGN-2012
- Precigen price target lowered to $5 from $7 at JMP Securities